Market Cap 516.36M
Revenue (ttm) 75.39M
Net Income (ttm) -287.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -381.39%
Debt to Equity Ratio 0.00
Volume 1,769,800
Avg Vol 2,246,756
Day's Range N/A - N/A
Shares Out 266.16M
Stochastic %K 27%
Beta 2.10
Analysts Strong Sell
Price Target $8.69

Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 3829 6230
Address:
The Mediaworks, 191 Wood Lane White City, London, United Kingdom
Michael_garic
Michael_garic Sep. 20 at 9:25 PM
$AUTL OK, options witching hour is gone and the market makers don't have to protect the 2.00 price point like they did the last two weeks. Maybe we break 2.00?? 2.50??
0 · Reply
KCclean
KCclean Sep. 20 at 1:47 PM
$AUTL broncos country
2 · Reply
Michael_garic
Michael_garic Sep. 19 at 11:15 AM
$AUTL IMO/Not advice...what would it take for AUTL to get rerated similar to what happened to IOVA: ALL franchise proving it can fund itself Beat / raise again on AUCATZYL Gross margin grinding toward the 65–70% peak Clearer path that they don’t need another large equity raise before Q4 2027 That shifts the stock from “cash-burn biotech” to “commercial compounder.” Autoimmune data that looks competitive. Q4 2026: longer CARLYSLE SLE follow-up (already slated for ACR) YE 2026: initial ALARIC amyloidosis data Q1 2027: first BOBCAT progressive MS look; fuller MS data 2H 2027 A clean safety + durability signal in SLE/LN or a surprising MS dataset is what would make people pay for the pipeline instead of only ALL sales. Pediatric ALL (CATULUS) Enrollment done YE 2026, pivotal-style data YE 2027, possible 2028 peds launch. That’s a real label expansion, not a science experiment. Capital-structure relief If revenue + the $15M opex save + the credit facility make dilution look optional
0 · Reply
Michael_garic
Michael_garic Sep. 19 at 11:06 AM
$AUTL some trivia: In the last three months (roughly mid-June through Friday, September 18), AUTL put together five separate stretches of two or more consecutive up closes. Those streaks were: Jul 29–30 (2 days) Aug 3–4 (2 days) Aug 6–7 (2 days) Aug 17–19 (3 days) Sep 17–18 (2 days) will this stretch to 3+ and set a new record? That’s 11 trading days that were part of a multi-day winning streak. Most up days in the period were isolated one-day pops, then a down day. Two-day (or longer) green runs have been infrequent — the current Thu–Fri bounce is one of the few.
0 · Reply
Michael_garic
Michael_garic Sep. 18 at 8:55 PM
$AUTL What is going on. 700K shares traded in the last 15 minutes with 400K in the last minute. Strange pattern unfolding here. Breakout next week?
1 · Reply
medinapj
medinapj Sep. 18 at 1:40 PM
$AUTL Let's buck the trend and get two green days in a row! 🤞🍀🤞🍀
2 · Reply
medinapj
medinapj Sep. 17 at 8:04 PM
$IOVA Great day 👏! Of course I would've liked if it held up a bit higher, but if you told me we'd break 10 today before the session started I'd be 🕺. I'm way more mad $AUTL can't hold/break $1.95 😡
1 · Reply
Michael_garic
Michael_garic Sep. 17 at 7:06 PM
$AUTL well if it follows the day trading pattern today we'll have a couple of hundred shares traded in the next hour as an attempt to drop sub 1.90. Works until it doesn't. You can make a few bucks that way. Stay long and wait for the catalysts to make the big returns.
2 · Reply
TSH2683
TSH2683 Sep. 17 at 3:05 PM
$AUTL buy the dip at 3:00 and sell premarket tommorow
2 · Reply
Michael_garic
Michael_garic Sep. 17 at 12:53 PM
$AUTL The last few sessions have been a true tug of war. Buyers in at 1.85 and sellers at 1.95. I'm not a day trader but these are the stats I've come up with using my limited tools. Maybe the more seasoned folks can add some color. This stock has a limited float, big swings are very possible. Near-term levels: Support Immediate / range floor: $1.83–$1.85 (recent daily lows and the level cited as daily support) Next: $1.82 (accumulated-volume support) Below that: $1.77, then the $1.61–$1.70 zone (longer-term moving averages and prior structure) Resistance Immediate / range ceiling: $1.94–$1.96 (recent highs in this band; several pivot R1 levels sit here) Next: $1.99–$2.03 Stronger overhead: $2.11–$2.12, then the $2.23–$2.30 and $2.38–$2.42 zones from earlier swing highs and moving-average clusters.
0 · Reply
Latest News on AUTL
Autolus Therapeutics Slides: Corporate presentation

Aug 18, 2026, 8:00 AM EDT - 4 weeks ago

Autolus Therapeutics Slides: Corporate presentation


Autolus Therapeutics Earnings Call Transcript: Q2 2026

Aug 11, 2026, 8:30 AM EDT - 5 weeks ago

Autolus Therapeutics Earnings Call Transcript: Q2 2026


Autolus Therapeutics Earnings release: Q2 2026

Aug 11, 2026, 8:30 AM EDT - 5 weeks ago

Autolus Therapeutics Earnings release: Q2 2026


Autolus Therapeutics Slides: Q2 2026

Aug 11, 2026, 8:30 AM EDT - 5 weeks ago

Autolus Therapeutics Slides: Q2 2026


Autolus Therapeutics Quarterly report: Q2 2026

Aug 11, 2026, 8:30 AM EDT - 5 weeks ago

Autolus Therapeutics Quarterly report: Q2 2026


Autolus Therapeutics reports Q2 EPS (15c), consensus (19c)

2026-08-11T11:20:11.000Z - 5 weeks ago

Autolus Therapeutics reports Q2 EPS (15c), consensus (19c)


Autolus Therapeutics Receives Prix Galien UK Award

Jun 12, 2026, 4:00 AM EDT - 3 months ago

Autolus Therapeutics Receives Prix Galien UK Award


Autolus Therapeutics Slides: Corporate presentation

May 21, 2026, 7:00 AM EDT - 4 months ago

Autolus Therapeutics Slides: Corporate presentation


Autolus Therapeutics reports Q1 EPS (27c), consensus (26c)

2026-05-14T12:45:01.000Z - 4 months ago

Autolus Therapeutics reports Q1 EPS (27c), consensus (26c)


Autolus Therapeutics Earnings Call Transcript: Q1 2026

May 14, 2026, 8:30 AM EDT - 4 months ago

Autolus Therapeutics Earnings Call Transcript: Q1 2026


Autolus Therapeutics Earnings release: Q1 2026

May 14, 2026, 8:30 AM EDT - 4 months ago

Autolus Therapeutics Earnings release: Q1 2026


Autolus Therapeutics Quarterly report: Q1 2026

May 14, 2026, 8:30 AM EDT - 4 months ago

Autolus Therapeutics Quarterly report: Q1 2026


Autolus Therapeutics Slides: Q1 2026

May 14, 2026, 8:30 AM EDT - 4 months ago

Autolus Therapeutics Slides: Q1 2026


Autolus Therapeutics to reduce workforce by approximately 13%

2026-04-29T22:04:39.000Z - 4 months ago

Autolus Therapeutics to reduce workforce by approximately 13%


Autolus Therapeutics Registration statement: Registration filing

Apr 13, 2026, 8:00 AM EDT - 5 months ago

Autolus Therapeutics Registration statement: Registration filing


Autolus Therapeutics Registration statement: Registration filing

Apr 13, 2026, 8:00 AM EDT - 5 months ago

Autolus Therapeutics Registration statement: Registration filing


Autolus Therapeutics Slides: Corporate presentation

Apr 13, 2026, 7:00 AM EDT - 5 months ago

Autolus Therapeutics Slides: Corporate presentation


Autolus Therapeutics files $150M mixed securities shelf

2026-04-13T10:06:09.000Z - 5 months ago

Autolus Therapeutics files $150M mixed securities shelf


Autolus Therapeutics Transcript: Status update

Apr 8, 2026, 1:00 PM EDT - 5 months ago

Autolus Therapeutics Transcript: Status update


Autolus Therapeutics Slides: Status update

Apr 8, 2026, 1:00 PM EDT - 5 months ago

Autolus Therapeutics Slides: Status update


Autolus Therapeutics Earnings Call Transcript: Q4 2025

Mar 27, 2026, 8:30 AM EDT - 5 months ago

Autolus Therapeutics Earnings Call Transcript: Q4 2025


Autolus Therapeutics Annual report: Q4 2025

Mar 27, 2026, 8:30 AM EDT - 5 months ago

Autolus Therapeutics Annual report: Q4 2025


Autolus Therapeutics Earnings release: Q4 2025

Mar 27, 2026, 8:30 AM EDT - 5 months ago

Autolus Therapeutics Earnings release: Q4 2025


Autolus Therapeutics Slides: Q4 2025

Mar 27, 2026, 8:30 AM EDT - 5 months ago

Autolus Therapeutics Slides: Q4 2025


Autolus Therapeutics reports Q4 EPS (34c), consensus (43c)

2026-03-27T11:36:34.000Z - 5 months ago

Autolus Therapeutics reports Q4 EPS (34c), consensus (43c)


Autolus Therapeutics initiated with a Buy at H.C. Wainwright

2026-02-17T11:11:16.000Z - 7 months ago

Autolus Therapeutics initiated with a Buy at H.C. Wainwright


Autolus Therapeutics Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:30 AM EST - 10 months ago

Autolus Therapeutics Earnings Call Transcript: Q3 2025


Autolus Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 8:30 AM EST - 10 months ago

Autolus Therapeutics Quarterly report: Q3 2025


Autolus Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 8:30 AM EST - 10 months ago

Autolus Therapeutics Earnings release: Q3 2025


Autolus Therapeutics Slides: Q3 2025

Nov 12, 2025, 8:30 AM EST - 10 months ago

Autolus Therapeutics Slides: Q3 2025


Autolus Therapeutics Earnings Call Transcript: Q2 2025

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Earnings Call Transcript: Q2 2025


Autolus Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Quarterly report: Q2 2025


Autolus Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Earnings release: Q2 2025


Autolus Therapeutics Slides: Q2 2025

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Slides: Q2 2025


Autolus Therapeutics Earnings Call Transcript: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Earnings Call Transcript: Q1 2025


Autolus Therapeutics Quarterly report: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Quarterly report: Q1 2025


Autolus Therapeutics Earnings release: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Earnings release: Q1 2025


Autolus Therapeutics Slides: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Slides: Q1 2025


Autolus Therapeutics Transcript: Status Update

Apr 23, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Transcript: Status Update


Autolus Therapeutics Press release: Status Update

Apr 23, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Press release: Status Update


Autolus Therapeutics Slides: Status Update

Apr 23, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Slides: Status Update


Autolus Therapeutics Earnings Call Transcript: Q4 2024

Mar 20, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Earnings Call Transcript: Q4 2024


Autolus Therapeutics Annual report: Q4 2024

Mar 20, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Annual report: Q4 2024


Autolus Therapeutics Earnings release: Q4 2024

Mar 20, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Earnings release: Q4 2024


Autolus Therapeutics Slides: Q4 2024

Mar 20, 2025, 8:30 AM EDT - 1 year ago

Autolus Therapeutics Slides: Q4 2024


Autolus Therapeutics Earnings Call Transcript: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Autolus Therapeutics Earnings Call Transcript: Q3 2024


Autolus Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Autolus Therapeutics Quarterly report: Q3 2024


Autolus Therapeutics Earnings release: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Autolus Therapeutics Earnings release: Q3 2024


Autolus Therapeutics Slides: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Autolus Therapeutics Slides: Q3 2024


Autolus Therapeutics Transcript: FDA Announcement

Nov 11, 2024, 8:30 AM EST - 1 year ago

Autolus Therapeutics Transcript: FDA Announcement


Autolus Therapeutics Press release: FDA Announcement

Nov 11, 2024, 8:30 AM EST - 1 year ago

Autolus Therapeutics Press release: FDA Announcement


Autolus Therapeutics Slides: FDA Announcement

Nov 11, 2024, 8:30 AM EST - 1 year ago

Autolus Therapeutics Slides: FDA Announcement


Autolus Therapeutics Earnings Call Transcript: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 2 years ago

Autolus Therapeutics Earnings Call Transcript: Q2 2024


Autolus Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 2 years ago

Autolus Therapeutics Quarterly report: Q2 2024


Autolus Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 2 years ago

Autolus Therapeutics Earnings release: Q2 2024


Autolus Therapeutics Slides: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 2 years ago

Autolus Therapeutics Slides: Q2 2024


Autolus Therapeutics Transcript: Status Update

Jun 1, 2024, 9:30 AM EDT - 2 years ago

Autolus Therapeutics Transcript: Status Update


Autolus Therapeutics Earnings Call Transcript: Q1 2024

May 17, 2024, 8:30 AM EDT - 2 years ago

Autolus Therapeutics Earnings Call Transcript: Q1 2024


Autolus Therapeutics Quarterly report: Q1 2024

May 17, 2024, 8:30 AM EDT - 2 years ago

Autolus Therapeutics Quarterly report: Q1 2024


Autolus Therapeutics Earnings release: Q1 2024

May 17, 2024, 8:30 AM EDT - 2 years ago

Autolus Therapeutics Earnings release: Q1 2024


Autolus Therapeutics Slides: Q1 2024

May 17, 2024, 8:30 AM EDT - 2 years ago

Autolus Therapeutics Slides: Q1 2024


Michael_garic
Michael_garic Sep. 20 at 9:25 PM
$AUTL OK, options witching hour is gone and the market makers don't have to protect the 2.00 price point like they did the last two weeks. Maybe we break 2.00?? 2.50??
0 · Reply
KCclean
KCclean Sep. 20 at 1:47 PM
$AUTL broncos country
2 · Reply
Michael_garic
Michael_garic Sep. 19 at 11:15 AM
$AUTL IMO/Not advice...what would it take for AUTL to get rerated similar to what happened to IOVA: ALL franchise proving it can fund itself Beat / raise again on AUCATZYL Gross margin grinding toward the 65–70% peak Clearer path that they don’t need another large equity raise before Q4 2027 That shifts the stock from “cash-burn biotech” to “commercial compounder.” Autoimmune data that looks competitive. Q4 2026: longer CARLYSLE SLE follow-up (already slated for ACR) YE 2026: initial ALARIC amyloidosis data Q1 2027: first BOBCAT progressive MS look; fuller MS data 2H 2027 A clean safety + durability signal in SLE/LN or a surprising MS dataset is what would make people pay for the pipeline instead of only ALL sales. Pediatric ALL (CATULUS) Enrollment done YE 2026, pivotal-style data YE 2027, possible 2028 peds launch. That’s a real label expansion, not a science experiment. Capital-structure relief If revenue + the $15M opex save + the credit facility make dilution look optional
0 · Reply
Michael_garic
Michael_garic Sep. 19 at 11:06 AM
$AUTL some trivia: In the last three months (roughly mid-June through Friday, September 18), AUTL put together five separate stretches of two or more consecutive up closes. Those streaks were: Jul 29–30 (2 days) Aug 3–4 (2 days) Aug 6–7 (2 days) Aug 17–19 (3 days) Sep 17–18 (2 days) will this stretch to 3+ and set a new record? That’s 11 trading days that were part of a multi-day winning streak. Most up days in the period were isolated one-day pops, then a down day. Two-day (or longer) green runs have been infrequent — the current Thu–Fri bounce is one of the few.
0 · Reply
Michael_garic
Michael_garic Sep. 18 at 8:55 PM
$AUTL What is going on. 700K shares traded in the last 15 minutes with 400K in the last minute. Strange pattern unfolding here. Breakout next week?
1 · Reply
medinapj
medinapj Sep. 18 at 1:40 PM
$AUTL Let's buck the trend and get two green days in a row! 🤞🍀🤞🍀
2 · Reply
medinapj
medinapj Sep. 17 at 8:04 PM
$IOVA Great day 👏! Of course I would've liked if it held up a bit higher, but if you told me we'd break 10 today before the session started I'd be 🕺. I'm way more mad $AUTL can't hold/break $1.95 😡
1 · Reply
Michael_garic
Michael_garic Sep. 17 at 7:06 PM
$AUTL well if it follows the day trading pattern today we'll have a couple of hundred shares traded in the next hour as an attempt to drop sub 1.90. Works until it doesn't. You can make a few bucks that way. Stay long and wait for the catalysts to make the big returns.
2 · Reply
TSH2683
TSH2683 Sep. 17 at 3:05 PM
$AUTL buy the dip at 3:00 and sell premarket tommorow
2 · Reply
Michael_garic
Michael_garic Sep. 17 at 12:53 PM
$AUTL The last few sessions have been a true tug of war. Buyers in at 1.85 and sellers at 1.95. I'm not a day trader but these are the stats I've come up with using my limited tools. Maybe the more seasoned folks can add some color. This stock has a limited float, big swings are very possible. Near-term levels: Support Immediate / range floor: $1.83–$1.85 (recent daily lows and the level cited as daily support) Next: $1.82 (accumulated-volume support) Below that: $1.77, then the $1.61–$1.70 zone (longer-term moving averages and prior structure) Resistance Immediate / range ceiling: $1.94–$1.96 (recent highs in this band; several pivot R1 levels sit here) Next: $1.99–$2.03 Stronger overhead: $2.11–$2.12, then the $2.23–$2.30 and $2.38–$2.42 zones from earlier swing highs and moving-average clusters.
0 · Reply
Michael_garic
Michael_garic Sep. 17 at 12:46 PM
$AUTL These are bank/investor conferences that are scheduled but no official notification that AUTL will be there: UBS Global Healthcare Nov 8–11, 2026 Palm Beach Gardens, FL Jefferies Global Healthcare (London) Nov 16–19, 2026 Piper Sandler 38th Annual Healthcare Dec 1–3, 2026 New York Evercore ISI HealthCON typically early Dec (2025 was Dec 2–4; 2026 not fully posted) usually Coral Gables / Miami area
0 · Reply
Michael_garic
Michael_garic Sep. 17 at 12:41 PM
$AUTL Q4 2026 Autolus (AUTL) catalysts, as the company has framed them: Clinical / conference data Early November — ACR Convergence 2026 (Nov 6–11, Orlando): next Phase 1 CARLYSLE update in severe refractory SLE / lupus nephritis (longer follow-up; they submitted this for ACR). This is the main autoimmune readout they have dated. Year-end 2026 — initial Phase 1 data from BOBCAT (obe-cel in progressive MS). Full dataset is guided for 2027. Year-end 2026 — initial Phase 1 data from ALARIC (AUTO8 / UCL collaboration in light-chain amyloidosis). Possible ASH 2026 (Dec 12–15, New Orleans): not formally guided as a 2026 Autolus data dump the way ACR is, but it is the natural slot for extra ALL / real-world (ROCCA) / pediatric CATULUS updates if abstracts land. Commercial / financial Q3 2026 earnings: estimated around early/mid November.
0 · Reply
TricksterT
TricksterT Sep. 16 at 8:22 PM
$AUTL in even deeper this time for some crazy reason. I have some ties to this stock and I just can’t shake it. I refuse to walk away without a 5x return….might bite me.
2 · Reply
diggs24
diggs24 Sep. 16 at 7:00 PM
0 · Reply
medinapj
medinapj Sep. 16 at 6:55 PM
$AUTL I had this in the 1.30's and IOVA in the 2's and remember thinking I had a much better chance getting back to even/making a profit with autl in the short term. Was not a great call to say the least....short interest decreasing and still 😞. SLE data next week? 🤞🙏🍀
2 · Reply
Tomthefirst
Tomthefirst Sep. 16 at 3:53 PM
$AUTL 👍👍👍
0 · Reply
XX1XX
XX1XX Sep. 16 at 3:34 PM
$AUTL added 10k yesterday at $1.89 - we made a higher low and we bounced off the standard dev line, that was good enough for me. I think the bottom is in and we move higher.
1 · Reply
Michael_garic
Michael_garic Sep. 16 at 11:31 AM
$AUTL short interest in AUTL continues to drop since the earnings report and is now less than it was this time last year: July 15 15.1M July 31 13.7M Aug 14 10.4M Aug 31 9.1M comparison of short shares as a percent of total shares AUTL 3.4% FATE 7.6% ALLO 17.1% IOVA 19.5% I guess this means a squeeze is much less likely with AUTL than IOVA or the others.
0 · Reply
TricksterT
TricksterT Sep. 15 at 9:56 PM
$AUTL any similarities between these two…I think so. $IOVA
4 · Reply
medinapj
medinapj Sep. 15 at 7:57 PM
$AUTL Another 2,700 shares added today; brought my average down a penny to $2.72 😂. Hoping for strong SLE and MS data to give us a kick 🍀
0 · Reply
PatriotTrader17
PatriotTrader17 Sep. 15 at 3:20 AM
$AUTL the secret is using the volume profile in conjunction with the fib extension.
1 · Reply
Michael_garic
Michael_garic Sep. 14 at 8:12 PM
$AUTL A lot of buyers in the last ten minutes... hope that continues this week.
0 · Reply